THERAPY DOSSIER · th-e899e6215580

Sarcandra glabra extract combined with lycopene

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 27631138 ↗2016Reported benefit

Sarcandra glabra combined with lycopene protect rats from lipopolysaccharide induced acute lung injury via reducing inflammatory response.

RatEndotoxin/LPSSprague-DawleyMale

Model: Lipopolysaccharide-induced acute lung injury

The combination reduced lipopolysaccharide-induced histopathological lung injury, improved antioxidative activity, lowered TNF-alpha and IL-6, suppressed MAPK and NF-kappaB activation and shifted the disturbed metabolic profile towards normal.

Extraction: extract · Supplied extraction confidence: 0.45. Machine-extracted fields require source verification.

Loading the evidence…